BriaCell Therapeutics (BCTX) files Form 25 to remove Warrants from Nasdaq

Rhea-AI Filing Summary

BriaCell Therapeutics Corp. filed a Form 25 notifying removal of its Warrant class from listing and registration on the Nasdaq Stock Market LLC.

Nasdaq certified compliance with 17 CFR 240.12d2-2 procedures to strike the class and the filing states the issuer complied with the Exchange's voluntary withdrawal requirements. The notice is signed by Tara Petta, Director.

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-40101

Issuer:	BriaCell Therapeutics Corp.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	Suite 300 - Bellevue Centre
	235 -15th Street
	West Vancouver	BRITISH COLUMBIA, CANADA	V7T 2X1
Telephone number:					604-921-1810

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Warrant

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2026-02-26	By	Tara Petta		Director
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Form 25 for BCTX state?

The filing notifies removal of the company's Warrant class from listing and registration on Nasdaq. Nasdaq certified compliance with 17 CFR 240.12d2-2 and the issuer attested to voluntary withdrawal requirements; the form is signed by Tara Petta, Director.

Who initiated the removal of BCTX warrants?

Nasdaq initiated the Form 25 filing certifying reasonable grounds to remove the Warrant class from listing. The filing also states the issuer complied with exchange rules governing voluntary withdrawal and the notification is signed by Tara Petta, Director.

Does the Form 25 affect BriaCell common stock or other securities?

This notice applies specifically to the Warrant class and does not reference common stock or other securities. No other classes are named and the filing confines its statements to compliance with 17 CFR 240.12d2-2 procedures for striking a class.

When is the removal effective according to the filing?

The header shows 'Expires: March 31, 2018' and the form includes a certification signed by Tara Petta. The filing text itself does not provide a labeled effective removal date or closing date for the Warrant class on Nasdaq in the provided excerpt.